bioRxivBioinformaticsPreprint
Progression Analysis of Disease with Survival (PAD-S) by SurvMap identifies different prognostic subgroups of breast cancer in a large combined set of transcriptomics and methylation studies
Jaume Forés-MartosiD, Beatriz Suay‐GarcíaiD, Raquel Bosch-RomeuiD, Maria Carmen Sanfeliu-AlonsoiD, Antonio FalcóiD, Joan ClimentiD
Abstract
Progression analysis of disease (PAD) is a methodology that incorporates the output of Disease-Specific Genomic Analyses (DSGA) to an unsupervised classification scheme based on Topological Data Analysis (TDA). PAD makes use of data derived from healthy individuals to split individual diseased samples into healthy and disease components. Then, the shape characteristics of the disease component are extracted trough the generation of a combinatioral graph by means of the Mapper algorithm. In this paper we introduce a new filtering function for the Mapper algorithm that naturally integrates information on genes linked to disease-free or overall survival. We propose a new PAD-extended methodology termed Progression Analysis of Disease with Survival (PAD-S) and implement it in an R package called SurvMap which allows users to carry out all the steps involved in PAD-S, as well as in traditional PAD analyses. We tested PAD-S methodology using SurvMap on a large combined transcriptomics breast cancer dataset demonstrating its capacity to identify sets of samples displaying highly significant differences in terms of disease free survival (p = 8 x 10-14) and idiosyncratic biological features. PAD-S and SurvMap were also able to identify sets of samples with significantly different relapse-free survivals and molecular profiles inside breast cancer intrinsic subgroups (luminal A, luminal B, Her2, and basal). Finally, to illustrate that PAD-S and SurvMap are general-purpose analysis tools that can be applied to different types of omics data, we also carried out analyses in a breast cancer methylation dataset derived from The Cancer Genome Atlas (TCGA) identifying groups of patients with significant differences in terms of overall survival and methylation profiles.
- organism: human
- assay: bulk RNA-seq
- assay: DNA methylation
- research focus: clustering
- research focus: differential expression
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses
Archana Bhardwaj, Claire Josse, … Kristel Van Steen·Scientific ReportsPeer-reviewed·Jun 30, 2022
- Individualized multi-omic pathway deviation scores using multiple factor analysis
Andréa Rau, Regina Manansala, … Paul Livermore Auer·BiostatisticsPeer-reviewed·Jun 30, 2020
- Meta-analysis of 1,200 transcriptomic profiles identifies a prognostic model for pancreatic ductal adenocarcinoma
Vandana Sandhu, Knut Jørgen Labori, … Benjamin Haibe‐Kains·JCO Clinical Cancer InformaticsPeer-reviewed·May 9, 2019
- Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Metaanalysis of transcriptional subtypes
Ines de Santiago, Christopher Yau, … Shivan Sivakumar·bioRxiv·Oct 5, 2017
- Computational discovery of tissue morphology biomarkers in very long-term survivors with pancreatic ductal adenocarcinoma
Jacob S. Sarnecki, Laura DeLong Wood, … Pei-Hsun Wu·bioRxiv·Oct 25, 2017
- Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival
Nishanth Ulhas Nair, Avinash Das, … Eytan Ruppin·Scientific ReportsPeer-reviewed·Jul 29, 2019